1. Home
  2. VANI vs BBIO Comparison

VANI vs BBIO Comparison

Compare VANI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.40

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

N/A

Current Price

$79.81

Market Cap

15.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VANI
BBIO
Founded
1998
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
15.9B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
VANI
BBIO
Price
$1.40
$79.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
25
Target Price
$3.50
$86.33
AVG Volume (30 Days)
180.6K
2.0M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,000,000.00
$502,076,000.00
Revenue This Year
N/A
$89.45
Revenue Next Year
N/A
$73.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
126.26
52 Week Low
$0.92
$46.81
52 Week High
$1.92
$93.42

Technical Indicators

Market Signals
Indicator
VANI
BBIO
Relative Strength Index (RSI) 53.79 45.74
Support Level $1.24 $78.90
Resistance Level $1.55 $85.34
Average True Range (ATR) 0.07 2.89
MACD -0.00 -0.63
Stochastic Oscillator 72.46 9.96

Price Performance

Historical Comparison
VANI
BBIO

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: